Premium
Repeated intravenous ketamine benefits patients with treatment‐resistant depression
Publication year - 2016
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30161
Subject(s) - ketamine , medicine , dosing , placebo , depression (economics) , antidepressant , regimen , anesthesia , treatment resistant depression , population , psychiatry , anxiety , alternative medicine , pathology , economics , macroeconomics , environmental health
Intravenous ketamine administered twice a week or three times a week resulted in sustained antidepressant effects compared with placebo in a group of patients with treatment‐resistant depression, a new study has found. Based on similar results between the two dosing frequencies, the researchers indicated that a twice‐weekly regimen could serve as an initial repeated‐dose strategy in this population.